Our Intellectual Property

Indication-Related Intellectual Property

We are establishing a broad, global intellectual property portfolio for our pipeline that, as of December 31, 2020, consisted of 22 patent families, six granted U.S. patents and 283 worldwide patents pending. This is notable considering the speed of our development model and establishes a strong foundation from which to build our business.

Our matrixed approach to IP is inclusive of trade secrets and trademarks and encompasses our product candidates (various constituents and amounts); indications; the development platform; manufacturing processes and technologies; and formulations. In our patents for compositions and methods of use, we seek claims of broad and narrow scope. For instance, some claims cover any composition containing a minimum of specified EMMs with activity, while other claims expressly cover specific product candidates by naming all the EMMs present.

We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continuing innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of leveraging EMMs for treating complex diseases and improving health.